Oncology

Partner
Indication
Stage
Summary
Resources
Genentech
Indication: Non-Small Cell Lung Cancer
Stage: Clinical
(Phase II)
Summary: High-dimensional epitope mapping and profiling of neoantigen-specific CD8 T cell responses in NSCLC patients during atezolizumab treatment
National Cancer Center of Singapore
Indication: Prostate Cancer
Stage: Clinical (Observational)
Summary: Comprehensive characterization of the systemic immune landscape in patients following radiotherapy or combination radiotherapy-ICB
University of Hong Kong
Indication: HCC
Stage: Preclinical
Summary: Investigation of mechanisms of resistance of liver tumors to infiltrating T cells in a mouse model of HCC
Mie University
Indication: Solid Tumors
Stage: Clinical
(Phase I/II)
Summary: Longitudinal tracking and deep phenotyping of NY-ESO-1 transgenic TCR T cells after adoptive transfer into solid tumor patients
Resources:

Manuscript under review

SITC poster 2019

Infectious Disease

Partner
Indication
Stage
Summary
Resources
Gilead Sciences
Indication: HBV
Stage: Clinical
(Phase I/II)
Summary: Assessment of longitudinal changes in the HBV-specific CD8 T cell response of patients with chronic HBV infection
Resources:

EASL poster 2020

Johns Hopkins University
Indication: COVID-19
Stage: Clinical (COVID-19 convalescent donor samples)
Summary: Viral epitope screening, identification and deep profiling of SARS-CoV-2 CD8 T cell responses in COVID-19 convalescent donors
Arcturus Therapeutics
Indication: COVID-19
Stage: Clinical
(Phase I)
Summary: Longitudinal monitoring of spike-specific CD8+ T cells and other immune cell subsets in subjects vaccinated with the mRNA vaccine candidate, ARCT-021
Resources:

Study initiated

Valo Therapeutics
Indication: COVID-19
Stage: Clinical
Summary: Identification and functional profiling of SARS-CoV-2 CD8+ T cell responses in PBMC from patients with past SARS-CoV-2 infection
Resources:

Study initiated

Top